Compare META & NVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | META | NVO |
|---|---|---|
| Founded | 2004 | 1923 |
| Country | United States | Denmark |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4T | 203.2B |
| IPO Year | 2012 | 2001 |
| Metric | META | NVO |
|---|---|---|
| Price | $550.68 | $46.81 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 40 | 11 |
| Target Price | ★ $838.63 | $51.00 |
| AVG Volume (30 Days) | ★ 15.1M | 12.4M |
| Earning Date | 04-29-2026 | 05-06-2026 |
| Dividend Yield | 0.31% | ★ 3.19% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 16.62 | N/A |
| Revenue | ★ $40,653,000,000.00 | N/A |
| Revenue This Year | $26.99 | N/A |
| Revenue Next Year | $18.21 | $3.70 |
| P/E Ratio | $32.84 | ★ $13.60 |
| Revenue Growth | ★ 47.09 | N/A |
| 52 Week Low | $520.26 | $35.12 |
| 52 Week High | $790.80 | $64.16 |
| Indicator | META | NVO |
|---|---|---|
| Relative Strength Index (RSI) | 38.93 | 49.67 |
| Support Level | $548.60 | $42.88 |
| Resistance Level | $614.41 | $50.94 |
| Average True Range (ATR) | 16.39 | 1.34 |
| MACD | -4.14 | -0.05 |
| Stochastic Oscillator | 16.64 | 60.60 |
Meta is the largest social media company in the world, boasting close to 4 billion monthly active users worldwide. The firm's "Family of Apps," its core business, consists of Facebook, Instagram, Messenger, and WhatsApp. End users can leverage these applications for a variety of different purposes, from keeping in touch with friends to following celebrities and running digital businesses for free. Meta packages customer data, gleaned from its application ecosystem and sells ads to digital advertisers. While the firm has been investing heavily in its Reality Labs business, it remains a very small part of Meta's overall sales.
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the world's leading provider of diabetes care products. Based in Denmark, the company manufactures and markets a variety of human and modern insulins for patients with diabetes, as well as injectable and oral GLP-1 therapies, across its obesity and diabetes care segment. Novo also has a rare disease segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.